All Releases
 |
Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap
Conference
May 22, 2013
|
14.8 KB |
|
| |
Buffalo, NY - May 22, 2013 - Cleveland BioLabs, Inc. (NASDAQ:CBLI) today announced that the Company is scheduled to present at the Second Annual Marcum LLP Microcap Conference, May 30, in New York, NY.
Neil Lyons, CPA, Chief Financial Officer of Cleveland BioLabs, will present the Company's oncology and biodefense programs on May 30 at ...
|
|
Cleveland BioLabs and Incuron Announce US and European Patent Allowances for Curaxins
May 14, 2013
|
17.0 KB |
|
| |
BUFFALO, N.Y., May 14, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) and Incuron, LLC, a joint venture between the Company and Bioprocess Capital Ventures, today announced the receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for the Curaxin U.S. Patent Application Number 12/993,018, titled "Inducing Cell D...
|
|
CORRECTION -- Cleveland BioLabs Reports First Quarter 2013 Financial Results and Development Progress
May 9, 2013
|
19.2 KB |
|
| |
BUFFALO, N.Y., May 9, 2013 (GLOBE NEWSWIRE) -- In a release issued earlier today under the same headline by Cleveland BioLabs, Inc. (Nasdaq:CBLI), the years in the column headers in the Consolidated Balance Sheets table were incorrect. With the exception of the headers, all other financials were correct. The corrected table follows:
...
|
|
Cleveland BioLabs Reports First Quarter 2013 Financial Results and Development Progress
May 9, 2013
|
27.2 KB |
|
| |
BUFFALO, N.Y., May 9, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today reported financial results and development progress for the first quarter ended March 31, 2013.
Cleveland BioLabs reported a net loss attributable to its common stockholders for the first quarter of 2013 of $9.8 million, or $0.22 per share of common stock...
|
|
Cleveland BioLabs Announces Appointment of Shareholder Representative to Board
May 8, 2013
|
17.5 KB |
|
| |
BUFFALO, N.Y., May 8, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced that its board of directors has appointed a shareholder representative, Randy S. Saluck, J.D., MBA as an independent director.
Yakov Kogan, Ph.D., MBA, Chief Executive Officer, stated, "Randy has been a shareholder of CBLI since 2009 and brings ...
|
|
Cleveland BioLabs, Roswell Park Announce Publication of Studies Defining Role of Liver in Activity of Entolimod (CBLB502)
May 1, 2013
|
20.8 KB |
|
| |
BUFFALO, N.Y., May 1, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) and Roswell Park Cancer Institute (RPCI) today announced the publication of studies identifying the liver as a key mediator of Entolimod's tissue-protective and anticancer activities in Proceedings of the National Academy of Sciences of the United States of America...
|
|
Cleveland BioLabs to Report First Quarter 2013 Financial Results and Provide Operational Update on May 9
Apr 30, 2013
|
14.6 KB |
|
| |
BUFFALO, N.Y., April 30, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced that on May 9, 2013 before the market opens, it will report its first quarter 2013 financial results for the period ended March 31, 2013, and will host a conference call at 10:00 a.m. ET.
Interested parties may participate by dialing 877-407-...
|
|
Cleveland BioLabs Announces Changes to Board of Directors
Apr 23, 2013
|
18.8 KB |
|
| |
BUFFALO, N.Y., April 23, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced that its board of directors has appointed Julia Brown and Anthony Principi as new independent directors and David Hohn, M.D., a current director, as Chairman of the board. Bernard Kasten, M.D. and Michael Fonstein, Ph.D., will retire from the boa...
|
|
Cleveland BioLabs Strengthens Clinical Development Team
Apr 8, 2013
|
22.7 KB |
|
| |
BUFFALO, N.Y., April 8, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) announced today the appointment of key clinical development and regulatory affairs executives to optimally position the company for successful development of its drug candidates. Jean Viallet, M.D., has joined the Company as Chief Development Officer, reporting t...
|
|
Cleveland BioLabs and Incuron Announce Notice of Allowance From FDA to Commence Clinical Testing With CBL0137
Apr 2, 2013
|
16.9 KB |
|
| |
BUFFALO, N.Y., April 2, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) and Incuron, LLC, a joint venture between the Company and Bioprocess Capital Ventures, today announced the receipt of a Notice of Allowance from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application for CBL0137.
A multi...
|
|
Cleveland BioLabs Reports Fourth Quarter and Fiscal 2012 Financial Results and Development Progress
Mar 14, 2013
|
28.7 KB |
|
| |
BUFFALO, N.Y., March 14, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today reported financial results and development progress for the fourth quarter and fiscal year ended December 31, 2012.
Cleveland BioLabs reported net income attributable to its common stockholders for the fourth quarter of 2012 of $3.1 million, or $0.07 p...
|
|
Cleveland BioLabs to Report Fiscal 2012 Financial Results and Provide Operational Update on March 14
Mar 8, 2013
|
18.3 KB |
|
| |
BUFFALO, N.Y., March 8, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced that on March 14, 2013 before the market opens, it will report its fiscal 2012 financial results for the period ended December 31, 2012, and will host a conference call at 10:00 a.m. EDT.
Interested parties may participate by dialing 877-4...
|
|
Cleveland BioLabs to Present at 15th Annual BIO CEO and Investor Conference
Feb 5, 2013
|
14.8 KB |
|
| |
BUFFALO, N.Y., Feb. 5, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced that the Company is scheduled to present at the 15th Annual BIO CEO and Investor Conference, February 11-12, in New York, NY.
Andrei Gudkov, Ph.D., D.Sci., Chief Scientific Officer of Cleveland BioLabs, wil...
|
|
Cleveland BioLabs to Present at BARDA and NIAID Sponsored Symposium on Development of Radiation Medical Countermeasures
Jan 24, 2013
|
15.6 KB |
|
| |
BUFFALO, N.Y., Jan. 24, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced that the Company was invited to present at a symposium hosted by the Biomedical Advanced Research and Development Authority (BARDA) and National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institu...
|
|
Cleveland BioLabs to Present at Noble Financial Eighth Annual Equity Conference
Jan 11, 2013
|
15.7 KB |
|
| |
BUFFALO, NY--(Marketwire -01/11/12)- Cleveland BioLabs, Inc. (NASDAQ: CBLI - News) today announced that the Company is scheduled to present at ...
|
|
Cleveland BioLabs to Present at Oppenheimer 23rd Annual Healthcare Conference
Dec 4, 2012
|
14.3 KB |
|
| |
BUFFALO, N.Y., Dec. 4, 2012 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced that the Company is scheduled to present at the Oppenheimer & Co. 23rd Annual Healthcare Conference, December 12-13, in New York, NY.
Neil Lyons, CPA, Chief Financial Officer of Cleveland BioLabs, will ...
|
|
Panacela Labs, a Subsidiary of Cleveland BioLabs, Signs Contract for Approximately $4.6 Million With Russian Ministry of Industry and Trade for Development of Xenomycins
Nov 27, 2012
|
17.3 KB |
|
| |
BUFFALO, N.Y., Nov. 27, 2012 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) and Panacela Labs, Inc. today announced award of a contract valued at 146 million rubles, or approximately $4.6 million (based on current exchange rates), with the Ministry of Industry and Trade of the Russian Federation for development of Xen...
|
|
Cleveland BioLabs Reports Third Quarter 2012 Financial Results and Development Progress
Nov 8, 2012
|
31.9 KB |
|
| |
BUFFALO, N.Y., Nov. 8, 2012 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today reported financial results and development progress for the third quarter and nine months ended September 30, 2012.
Cleveland BioLabs reported a net loss attributable to its common stockholders for the third quarter of 2012 of ...
|
|
Cleveland BioLabs Announces Publication of Studies on Effect of Entolimod™ (CBLB502) on Graft-Versus-Tumor Activity in Models of Allogeneic Bone Marrow Transplantation
Nov 6, 2012
|
22.5 KB |
|
| |
BUFFALO, N.Y., Nov. 6, 2012 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) announced today the online publication in the Journal of Immunology of a study demonstrating efficacy of Entolimod™ (previously known as CBLB502) in improving the graft-versus-tumor (GVT) activity of allogeneic bone marrow transpla...
|
|
Cleveland BioLabs to Report Third Quarter Financial Results and Provide Operational Update on November 8
Oct 30, 2012
|
17.9 KB |
|
| |
BUFFALO, N.Y., Oct. 30, 2012 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced that on November 8, 2012, before the market opens, it will report its second quarter financial results for the period ended September 30, 2012 and will host a conference call at 10:00 a.m. ET.
Interested parties may ...
|
|
|
= add release to Briefcase
|
